People

Vice President and Global Head of R&D Oncology at Servier and former Head of Cell Therapy and Early Translational Oncology at Takeda. Advises Ingenix on translational and clinical strategy in oncology.

Computer science PhD and former senior engineering manager at Snowflake following its acquisition of Applica. Leads AI research and core architecture development at Ingenix.

Computational biology researcher formerly a senior scientist at InSilico Medicine and director of AI and Data Science at Ardigen. Leads Ingenix’s scientific work at the intersection of AI and biology.

Former EMEA lead for Healthcare & Life Sciences Startups at Amazon Web Services and co-founder of AION Labs. Leads commercial strategy, partnerships and Ingenix’s Qualified Access Program.

Co-founder and former CTO of Applica, where he developed multimodal document-understanding models. Leads engineering and architecture of Ingenix’s Biological Reasoning Engine.

Co-founder and former CEO of Applica, acquired by Snowflake in 2022. Leads Ingenix’s overall direction, strategy and scientific vision.

Raul G. Nogueira is named on Anaconda Biomed’s current public scientific advisory board. The issuer describes the clinician’s external clinical affiliation as Endowed Professor & Division Chief of Cerebrovascular Medicine, and Professor of Neurology and Neurosurgery, University of Pittsburgh. Director, UPMC Stroke Institute. Past President of the Society of Vascular and Interventional Neurology and the former Editor-In-Chief of the Interventional Neurology journal.. This is an advisory relationship rather than company employment.

Serves as Board Member at Paradigm Health, according to its current team directory.

Ben Patz is co-founder and general managing partner of DeepWork Capital, according to his own manager biography. He founded ColemanTechnologies, sold to Presidio in2009, and subsequently served as Presidio COO through2013. His engineering research included fuzzy logic and neural-network control systems, and he led UCF’s DARPA Urban Challenge team; he holds electrical-engineering degrees from UCF and Rensselaer. Circuitry.ai announced in its October1,2025 seed release that he would join its board. That announced appointment is source-qualified rather than asserted as independently confirmed current2026 board service. His existing authentic manager photograph and all external roles are preserved.

Chief financial officer at NewVale Capital. Previously a director at CFO Fund Services, later acquired by SS&C, she managed accounting, tax and investor reporting for venture and private-equity funds. She began as a PwC auditor and holds accounting and MBA degrees from the University of Denver.

Mark Corrigan is a Wave director and strategic advisor to Ceretype Neuromedicine. He co-founded Tremeau Pharmaceuticals and previously led Correvio and held executive positions at Zalicus, Sepracor and Pharmacia. Board-certified in psychiatry and neurology, he earned his undergraduate and medical degrees at the University of Virginia and trained at Maine Medical Center and Cornell.

David Silbersweig is published by Samphire Neuroscience as Prof David Silbersweig, MD Harvard, Brigham & Women’s Head of NeuroPsych. The company lists this affiliation within its scientific-adviser and key-collaborator group, not its statutory board.

Hannah Zheng is a senior research associate at Modulo Bio according to its current public team. Her own February2025 post confirms the company’s USD500K ALS Association grant supporting IND-enabling studies of its CSF1R inhibitor. The grant is company research funding rather than a personal financial investment.

Apuleyo Yanez is a research associate at Modulo Bio, as confirmed by its current named staff roster and original portrait. The biotechnology company studies the neuroimmune system using stem-cell models, neurobiology, multiomics and machine learning to develop neuroprotective therapeutic approaches.

Brent Wilkinson, PhD, is a scientist at Modulo Bio according to the company’s current public team. Modulo’s interdisciplinary research programme combines neurobiology, stem-cell engineering and computational analysis to identify drugs that modulate microglia and protect neurons in neurological disease.

Joseph (Joe) Wagner, PhD, is Modulo Bio’s chief development officer, announced June3,2025 and confirmed in its current team. He has more than25years of biotechnology experience and previously led R&D, software engineering and data science as chief scientific officer at Notable Labs. Earlier executive roles included BriaCell Therapeutics and OncoCyte. His experience covers therapeutic development and precision medicine across neurology, oncology and other disease areas.

Steven Schaffert, PhD, is Modulo Bio’s principal data scientist according to its current published team. The company’s drug-discovery platform uses computational analysis, machine learning and experimental neurobiology to understand microglial cell states and therapeutic opportunities in neurodegenerative disease.

Karen Sachs, PhD, is director of computational biology at Modulo Bio, as named in the company’s current public team. The company combines single-cell multiomics and machine learning with experimental neuroimmune models to identify biomarkers, biological relationships and therapeutic targets for neurological diseases.

Scott Patterson is Modulo Bio’s CTO and co-founder. The company’s launch biography identifies earlier service as Vice President of Engineering at Counsyl. Its discovery platform integrates software, automation and AI with stem-cell biology to map the neuroimmune system. The November2024 legal issuer filing names Alexander Scott Patterson, anchoring the same founder identity.

Ryan Lim, PhD, is Modulo Bio’s director of biology and principal investigator on its ADDF-supported CSF1R inhibitor programme. His own funding announcement describes preclinical development, biomarker validation and advancement toward clinical studies for ALS and frontotemporal dementia. The company’s current published team independently confirms his leadership position.

Justin Ichida advises Spinogenix on science. His research at USC combines stem-cell models, cellular reprogramming and genetics to study ALS, frontotemporal dementia and potential neurodegenerative-disease therapies. He also co-founded Modulo Bio. Justin Ichida is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation John Douglas French Foundation Endowed Professor of Stem Cell Biology and Regenerative Medicine, University of Southern California. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Mike (Michael) Horowitz is CEO and co-founder of Modulo Bio. The company’s own launch statement describes his personal motivation after witnessing a close friend’s mother develop frontotemporal dementia. He leads a biotechnology company combining patient-derived neuroimmune models with software, automation and AI to discover drugs that reprogram microglia. The legal issuer’s SEC filing uses Michael Horowitz for this same executive.

Nina Draeger, PhD, is a senior scientist at Modulo Bio according to its current published team. She is a biochemist with research interests in neurodegeneration. Modulo’s discovery programme integrates stem-cell neuroimmune models, neurobiology and computational analysis to develop therapeutic approaches for neurological diseases.

Partner and co-lead of Dementia Discovery Fund, joining SV in 2026 after leading Takeda Ventures; Montara Therapeutics board member.

Bill Yelle is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation FireCyte Therapeutics, Founding CEO. Further career details and exact affiliation dates are not published in this source.

Meredith Fisher is a Partner at Mass General Brigham Ventures, working on early company development and investment. Her published biography lists board service at BraveBio, ClarisBio, CrossTalk, Falcon Bio, Sena and Violet, with a co-founder and chief-executive affiliation at Violet. It separately identifies observer positions at Altido, Mediar and Monimoi.

Dementia Discovery Fund venture partner, also known as James B. Summers; former AbbVie neuroscience research vice president and biotechnology director and scientific adviser.

Stefan Larson is published by Sectoral Asset Management as Venture Partner. Became Venture Partner in2024 after joining the manager as Partner in2018. Holds a Stanford biophysics PhD and earlier McGill and Toronto science degrees, with entrepreneurial and venture-investing experience.

Michel Michaelides is Eye2Gene’s Chief Medical Officer and co-founder, a Moorfields consultant and UCL ophthalmology professor. He contributes inherited-retinal-disease expertise and clinical-trial leadership; academic research funding is not company financing.

Business Development Division Director and Venture Capitalist at JIC VGI, joined in 2025. Previously supported startup R&D at NEDO from 2021 and worked on startup ecosystem hub selection at the Cabinet Office in 2019. Holds a master’s in technology management from Ritsumeikan University.

Francisca Gilmore-Yulee: Vice President, Investment & Platform at f7 Ventures.

Kelly Graziadei: Founding Partner & Managing Member at f7 Ventures.

Joanna Lee Shevelenko: Founding Partner & Managing Member at f7 Ventures.

Yilin Huo: Associate at S2G Investments.

Walter Robb: Operating Partner at S2G Investments.

Vikram Sharma: Operating Partner at S2G Investments.

Victoria Liu: Associate at S2G Investments.

Tonya Bakritzes: Chief Marketing Officer at S2G Investments.

Sumeeta Salvador: Senior Associate, Ecosystem at S2G Investments.

Sean Nguyen: Senior Staff Data Scientist at S2G Investments.

Sanjeev Krishnan: Managing Partner at S2G Investments.

Rosario Bennett: Senior Associate at S2G Investments.

Priyanka Duvvuru: Principal at S2G Investments.

Nick Curran: Vice President at S2G Investments.

Mya Stanislas: Impact Associate at S2G Investments.

Monica Jensen: Chief Financial Officer at S2G Investments.

Mohit Kalra: General Counsel at S2G Investments.

Mitch Worden: Vice President, Ecosystem at S2G Investments.

Miles Russo: Senior Associate at S2G Investments.

Mike Wise: Principal at S2G Investments.

Mike Gilkes: Principal at S2G Investments.

Michelle Morales: Senior Associate at S2G Investments.

Maura Wells: Vice President, Investor Relations at S2G Investments.

Matthew Walker: Managing Director at S2G Investments.

Matt LaPorta: Associate at S2G Investments.

Mary DaSilva: Chief People Officer at S2G Investments.

Mary Catherine Daniels: Executive Assistant at S2G Investments.

Marisa Sweeney: Principal at S2G Investments.

Mackenzie Longo: Executive Assistant at S2G Investments.

Lisa Rosen: Fund Controller at S2G Investments.

Larsen Mettler: Managing Director at S2G Investments.

Kevin Vincent: Chief Compliance Officer at S2G Investments.

Kevin O’Shaughnessy: Vice President, Digital Marketing at S2G Investments.

Kevin Lo: Operating Partner at S2G Investments.

Katie Stanton: Vice President, Finance & Operations at S2G Investments.

Katie Petrakos: Executive Assistant at S2G Investments.

Kate Danaher: Managing Director at S2G Investments.

Jusleen Huang: Associate at S2G Investments.

Joyce Kim: Counsel, Investments at S2G Investments.

Jinchen Zou: Senior Associate at S2G Investments.

Jessica Murphy: Principal, Director of Community at S2G Investments.

Jake Reznick: Vice President at S2G Investments.

Izzy Johnson: Senior Fund Accountant at S2G Investments.

Henry Hu: Associate at S2G Investments.

Heather McPherson: Principal, Director of Impact at S2G Investments.

Grant Leslie: Operating Partner, Government & Policy at S2G Investments.

Gokul Raghavan: Principal at S2G Investments.

Gage Wallace: Executive Assistant at S2G Investments.

Francis Villante: Vice President at S2G Investments.

Francis O’Sullivan: Managing Director at S2G Investments.

Elizabeth Andrews: Associate at S2G Investments.

Deanna Meirink: Office Coordinator at S2G Investments.

Dan Ripma: Principal at S2G Investments.

Cristina Rohr: Managing Director at S2G Investments.

Chuck Templeton: Managing Partner at S2G Investments.

Chris Marshall: Head of AI & Technology Solutions at S2G Investments.

Caroline Hogan: Associate at S2G Investments.

Brian O’Connor: Managing Director & Co-Head at S2G Investments.

Benazeer Bennardo: Executive Assistant at S2G Investments.

Bella Zimmer: Senior Fund Accountant at S2G Investments.

Bala Nagarajan: Managing Director at S2G Investments.

August O'Hern: Senior Associate at S2G Investments.

Audre Kapacinskas: Principal, Head of Ecosystem Development at S2G Investments.

Andrea Woodside: Managing Director & Co-Head at S2G Investments.

Ally Dunne: Vice President, Communications at S2G Investments.

Alexandra Miller: Executive Assistant at S2G Investments.

Aaron Rudberg: Managing Partner at S2G Investments.

Lisa Genasci: Senior Adviser at Cibus Capital.

Justin Mundy: Senior Adviser at Cibus Capital.

Jonathan Musselwhite: Senior Adviser at Cibus Capital.

Tom Ritchie: Investment Director at Cibus Capital.

Terence Ngwerume: Consultant Investment Analyst at Cibus Capital.

Tarquin Stephenson: Consultant Venture Associate at Cibus Capital.

Zac Banducci: Consultant Investment Analyst at Cibus Capital.

Susie Harrison: Office Coordinator at Cibus Capital.

Robert Appleby: Founder and Chief Investment Officer at Cibus Capital.

Priyesh Malavia: Financial Controller at Cibus Capital.

Olga Teteruk: Consultant Senior Investment Associate at Cibus Capital.

Niamh Finch: Legal Counsel at Cibus Capital.

Mario Gao: Investment Associate at Cibus Capital.

Manuel Vilches: Senior Investment Associate at Cibus Capital.

Lucy Gray: Investor Relations Associate at Cibus Capital.

Jeremy Alun-Jones: Chief Operating Officer at Cibus Capital.

Jason Silm: Head of Agriculture at Cibus Capital.

Hugo Kelly: Investment Director at Cibus Capital.

Georgina Kuhle: Head of Impact at Cibus Capital.

Fred Appleby: Head of Operations at Cibus Capital.

Ella Exley: Investor Relations Analyst at Cibus Capital.

Damon Petrie: Consultant Investment Director at Cibus Capital.

Catherine Griggs: Cibus Representative on GP Boards at Cibus Capital.

Archie Burgess: Investment Director at Cibus Capital.

Annie Rainsford: General Counsel at Cibus Capital.

Alastair Cooper: Head of Venture at Cibus Capital.

Nolan Shah: Associate at Spero Ventures.

Stephen Wemple: Principal at Spero Ventures.

Marc Tarpenning: Venture Partner at Spero Ventures.

Sara Eshelman: General Partner at Spero Ventures.

Andrew Parker: General Partner at Spero Ventures.

Robert Stevens: Independent Director at Corvus Robotics.

Arthur Chow: Principal at S2G Investments. Also a board director at Corvus Robotics.

Shripriya Mahesh: General Partner at Spero Ventures. Also a board director at Corvus Robotics.

Jackie Wu: Co-Founder & Board Director at Corvus Robotics.

Eric Andreas: Head of Finance at Corvus Robotics.

Andrew Burer: Head of Marketing at Corvus Robotics.

Parker Lusk: Head of Autonomy at Corvus Robotics.

Michael McSpedon: Chief Revenue Officer at Corvus Robotics.

Mohammed Kabir: CEO & Co-Founder at Corvus Robotics.

Eric Reich is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Rob Shavell is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Dan Magnuszewski is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Ariel Diaz is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Aaron White is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Jake Epstein is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Joe Lemay is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Brad McNamara is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

David Martirano is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Rob Biederman is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Matt Joblon is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Enrico Palmerino is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Vishal Sunak is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Mike Volpe is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Jack Greco is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Lee Hower is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

John Chory is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Joe Caruso is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Serguei Netessine is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Aaron Newman is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Wayne Chang is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Shawn Gee is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Andy Palmer is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Rich Miner is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Mike Salguero is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Questlove is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Jason Robins is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.